Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.

@article{Melis1992IpriflavoneAL,
  title={Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.},
  author={Gian Benedetto Melis and Anna Maria Paoletti and Riccardo Bartolini and M Tosti Balducci and Giovan Battista Massi and Vincenzina Bruni and Angelamaria Becorpi and Silva Ottanelli and Pm. Fioretti and Marco Gambacciani},
  journal={Bone and mineral},
  year={1992},
  volume={19 Suppl 1},
  pages={
          S49-56
        }
}
Estrogen replacement therapy can counteract all postmenopausal symptoms. While low estrogen doses (0.15-0.30 mg of conjugated estrogens/day) can counteract neurovegetative and psychological symptoms, higher estrogen doses (at least 0.625 mg of conjugated estrogens/day) are required to prevent bone mineral loss in postmenopausal women. However, if contra-indications to high estrogen doses exist, drugs other than estrogens can represent a suitable treatment for postmenopausal osteoporosis both… CONTINUE READING
BETA